CMG Pharmaceutical Co. Ltd (058820) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.08 Billion ≈ $-2.77 Million USD) by net assets (₩201.55 Billion ≈ $136.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 058820 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
CMG Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how CMG Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CMG Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
N. Varveris-Moda Bagno S.A
AT:MODA
|
0.043x |
|
I-Berhad
KLSE:4251
|
0.032x |
|
Wam Active Ltd
AU:WAA
|
0.010x |
|
BRIG.M3 EUROP.ACQ.A-0001
F:KN2
|
N/A |
|
Prime Securities Limited
NSE:PRIMESECU
|
-0.056x |
|
Decidr Ai Industries Ltd
AU:DAI
|
-0.079x |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
-0.092x |
|
Volati AB
ST:VOLO-PREF
|
-0.060x |
Annual Cash Flow Conversion Efficiency for CMG Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of CMG Pharmaceutical Co. Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see CMG Pharmaceutical Co. Ltd (058820) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩201.55 Billion ≈ $136.59 Million |
₩-11.02 Billion ≈ $-7.47 Million |
-0.055x | -3672.48% |
| 2024-12-31 | ₩189.54 Billion ≈ $128.45 Million |
₩290.09 Million ≈ $196.59K |
0.002x | -92.55% |
| 2023-12-31 | ₩190.23 Billion ≈ $128.92 Million |
₩3.91 Billion ≈ $2.65 Million |
0.021x | -23.03% |
| 2022-12-31 | ₩184.95 Billion ≈ $125.34 Million |
₩4.94 Billion ≈ $3.35 Million |
0.027x | -12.40% |
| 2021-12-31 | ₩184.70 Billion ≈ $125.17 Million |
₩5.63 Billion ≈ $3.81 Million |
0.030x | +87.47% |
| 2020-12-31 | ₩181.13 Billion ≈ $122.75 Million |
₩2.94 Billion ≈ $2.00 Million |
0.016x | +3.72% |
| 2019-12-31 | ₩180.16 Billion ≈ $122.09 Million |
₩2.82 Billion ≈ $1.91 Million |
0.016x | +83.76% |
| 2018-12-31 | ₩103.98 Billion ≈ $70.47 Million |
₩886.78 Million ≈ $600.96K |
0.009x | -57.12% |
| 2017-12-31 | ₩97.94 Billion ≈ $66.38 Million |
₩1.95 Billion ≈ $1.32 Million |
0.020x | -12.90% |
| 2016-12-31 | ₩101.11 Billion ≈ $68.52 Million |
₩2.31 Billion ≈ $1.56 Million |
0.023x | -55.67% |
| 2015-12-31 | ₩46.81 Billion ≈ $31.72 Million |
₩2.41 Billion ≈ $1.63 Million |
0.052x | +248.22% |
| 2014-12-31 | ₩49.00 Billion ≈ $33.21 Million |
₩724.89 Million ≈ $491.25K |
0.015x | -- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more